The results of the agglutination are
presented in Table 1. As can be seen, the tested product
was efficient on average against 56% bacterial strains,
while the highest activity was observed against the
most wide-spread and dangerous pathogens E. coli,
S. enteritidis, S. typhimurium, and Clostridium spp.
Thus, in vivo health-protective and performance-improving
activities of Bio-Mos® described in the cited
articles, was fully corroborated by the performed in
vitro tests. Recently, the agglutinating capacity towards
various enteric pathogens was compared for Bio-Mos®
and several other mannose-containing compounds
(Newman, 2006) using the specifically designed
aggregation rate coefficient (ARC) method. The results
of ARC assay demonstrated superior efficacy of BioMos®
in binding and agglutination of bacteria.